Retinoic acid receptor modulators: a perspective on recent advances and promises

Bibliography

• Germain P, Chambon P, Eichele G, The pharmacology and classification of the nuclear receptor superfamily. RETINOIC ACID RECEPTORS (RARs). Pharmacol Rev 2006;58:712-25
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, The pharmacology and classification of the nuclear receptor superfamily. RETINOID X RECEPTORS (RXRs). Pharmacol Rev 2006;58:760-72
   PubMed Web of Science ®Google Scholar
• Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007;27(5):691-70
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 2006;20(11):1405-28
   Google Scholar
• Gronemeyer H, Gustafsson J-A, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3:950-64
   PubMed Web of Science ®Google Scholar
• Bourguet W, de Lera AR, Gronemeyer H. Inverse agonists and antagonists of retinoid receptors. Method Enzymol 2010;485:161-95
   Google Scholar
• Altucci L, Leibowitz MD, Ogilvie KM, H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007;6:793-810
   PubMed Web of Science ®Google Scholar
• Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000;21:381-8
   PubMed Web of Science ®Google Scholar
• Huang P, Chandra V, Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Ann Rev Physiol 2010;72:247-72
   PubMed Web of Science ®Google Scholar
• Bourguet W, Vivat V, Wurtz J-M, Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000;5:289-98
   PubMed Web of Science ®Google Scholar
• Nahoum V, Perez E, Germain P, Modulators of the structural dynamics of RXR to reveal receptor function. Proc Natl Acad Sci USA 2007;104:17323-8
   PubMed Web of Science ®Google Scholar
• Perez-Santin E, Germain P, Quillard F, Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers. J Med Chem 2009;52:3150-8
   PubMed Web of Science ®Google Scholar
• Germain P, Gaudon C, Pogenberg V, Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem Biol 2009;16:479-89
   PubMed Web of Science ®Google Scholar
• le Maire A, Teyssier C, Erb C, A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat Struct Mol Biol 2010;17:801-7
   PubMed Web of Science ®Google Scholar
• de Lera AR, Bourguet W, Altucci L, Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007;6:811-20
   PubMed Web of Science ®Google Scholar
• Gehin M, Vivat V, Wurtz J-M, Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol 1999;6:519-29
   PubMed Web of Science ®Google Scholar
• Alvarez S, Khanwalkar H, Alvarez R, C3 halogen and C8′′ substituents on stilbene arotinoids modulate retinoic acid receptor subtype function. ChemMedChem 2009;4:1630-40
   Google Scholar
• Garcia J, Khanwalkar H, Pereira R, Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors. ChemBioChem 2009;10:1252-9
   PubMed Web of Science ®Google Scholar
• Klein ES, Pino ME, Johnson AT, Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J Biol Chem 1996;271:22692-6
   PubMed Web of Science ®Google Scholar
• Tsang KY, Sinha S, Liu X, Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity. US20050165095; 2005
   Google Scholar
• Li Y, Hashimoto Y, Agadir A, Identification of a novel class of retinoic acid receptor beta-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer. J Biol Chem 1999;274:15360-6
   PubMed Web of Science ®Google Scholar
• Biadatti T, Dumais L, Soulet C, Preparation of [1,1′:3,3′]terphenyl-4-carboxylic acid and esters as novel ligands modulating retinoic acid receptors (RARs) and use thereof in human medicine and in cosmetics. WO2006066978A1; 2006
   Google Scholar
• Olsson R, Piu F, Winther B. Preparation of cycloalka-fused imidazoles with activity at retinoic acid receptors. WO2008064136A2; 2008
   Google Scholar
• Piu F, Gauthier NK, Olsson R, Identification of novel subtype selective RAR agonists. Biochem Pharmacol 2005;71:156-62
   Google Scholar
• Lund BW, Piu F, Gauthier NK, Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem 2005;48:7517-19
   PubMed Web of Science ®Google Scholar
• Olsson R, Piu F, Gundersen B. Preparation of benzoic acid derivatives as modulators of retinoic acid receptors. WO2007009083A2; 2007
   Google Scholar
• Lund BW, Knapp AE, Piu F, Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta2 ligands. J Med Chem 2009;52:1540-5
   PubMedGoogle Scholar
• Astapoba I, Lee LJ, Morales C, The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo. Proc Natl Acad Sci USA 2008;105:19544-9
   Google Scholar
• Nofsinger RR, Li P, Hong S-H, SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. Proc Natl Acad Sci USA 2008;105:20021-6
   PubMedGoogle Scholar
• Nagy L, Schwabe JWR. Mechanism of the nuclear receptor molecular switch. Trends Biomed Sci 2004;29:317-24
   PubMed Web of Science ®Google Scholar
• Tramposch KM, Nair X, Marinier A, Retinoid antagonists and uses thereof. USP20016319948; 2001
   Google Scholar
• Hammond LA, Brown G, Keedwell RG, The prospects of retinoids in the treatment of prostate cancer. Anti Cancer Drugs 2002;13:781-90
   PubMed Web of Science ®Google Scholar
• Beehler BC, Hei Y-J, Chen S, Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J Rheumatol 2003;30:355-63
   Google Scholar
• Lee M-O, Hobbs PD, Zhang X-K, Synthetic retinoid antagonist inhibits the human immunodeficiency virus type 1 promoter. Proc Natl Acad Sci USA 1994;91:5632-6
   PubMed Web of Science ®Google Scholar
• Schupp M, Curtin JC, Kim RJ, A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity. Mol Pharmacol 2007;71:1251-7
   PubMed Web of Science ®Google Scholar
• Chandra V, Huang P, Hamuro Y, Structure of the intact PPARgamma-RXRalpha nuclear receptor complex on DNA. Nature 2008;456:350-6
   PubMed Web of Science ®Google Scholar
• Nagpal S, Friant S, Nakshatri H, RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 1993;12:2349-60
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93
   PubMed Web of Science ®Google Scholar
• Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meet resistance. Oncogene 2003;22:7305-15
   PubMed Web of Science ®Google Scholar
• Alvarez S, Germain P, Alvarez R, Structure, function and modulation of RARbeta, a tumour supressor. Int J Biochem Cell Biol 2007;39:1406-15
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
   PubMed Web of Science ®Google Scholar
• Gediya LK, Khandelwal A, Patel J, Design, ssynthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with rnhanced anticancer activities in breast and prostate cancer cells in vitro. J Med Chem 2008;51:3895-904
   PubMed Web of Science ®Google Scholar
• Lu Y, Bertran S, Samuels TA, Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARalpha agonist AM580. Oncogene 2010;29:3665-76
   Google Scholar
• Huang S, Laoukili J, Epping MT, ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009;15:328-40
   PubMed Web of Science ®Google Scholar
• Holzel M, Huang S, Koster J, NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142:218-29
   PubMed Web of Science ®Google Scholar
• Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008;9:541-53
   PubMed Web of Science ®Google Scholar
• Allsop TE, Bunnage ME, Fish PV. Small molecule modulation of stem cells in regenerative medicine: recent applications and future directions. Med Chem Commun 2010;1:16-29
   Google Scholar
• Anastasia L, Pelissero G, Venerando B, Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ 2010;17:1230-7
   PubMed Web of Science ®Google Scholar
• Kennedy K, Porter T, Mehta V, Retinoic acid enhances skeletal muscle progenitor formation and bypasses inhibition by bone morphogenetic protein 4 but not dominant negative beta-catenin. BMC Biol 2009;7:67
   Google Scholar
• Wong L-F, Yip PK, Battaglia A, Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci 2006;9:243-50
   PubMed Web of Science ®Google Scholar
• Lee H-P, Casadesus G, Zhu X, All-trans-retinoic acid as a novel therapeutic strategy for Alzheimer disease. Expert Rev Neurother 2009;9:1615-21
   PubMed Web of Science ®Google Scholar
• Stosic-Grujicic S, Cvjeticanin T, Stojanovic I. Retinoids differentially regulate the progression of autoimmune diabetes in three preclinical models in mice. Mol Immunol 2009;47:79-86
   Google Scholar
• Thacher SM, Vasaudevan J, Chandraratna RAS. Therapeutic applications for ligands of retinoid receptors. Cur Pharm Des 2000;6:25-58
   PubMed Web of Science ®Google Scholar